TNB-486

TNB-486 (also known as AZD0486) "is a novel CD19xCD3 bispecific T-cell engager (TCE) that incorporates a unique anti-CD3 moiety designed to reduce cytokine release syndrome by binding to T-cells with low affinity". The drug is developed for cancer by AstraZeneca since its acquisition of TeneoTwo in 2022.